Firebrick Pharma (ASX:FRE) has secured its first-ever regulatory approval for Nasodine nasal spray, greenlighting its entry into the Indonesian market.
The Indonesian Government has classified the product as an 'antiseptic' within the 'Household Health Supplies' category, allowing for immediate importation and marketing across the archipelago.
The approval follows a rigorous submission process to the Indonesian Ministry of Health, facilitated by local regulatory agents PT Pyridam Farma and PT Mursmedic.
Under a newly executed product registration services agreement with Pyridam, Firebrick gains essential access to the Indonesian market, which, with a population of 285 million, represents the largest economy in Southeast Asia and the fourth most populous nation globally.
Executive Chairman Dr Peter Molloy described the announcement as a "pivotal event" and a "massive value inflection point" for the company.
While the approval is effective immediately, Firebrick must now finalise local-language packaging and secure a strategic marketing partner to manage domestic distribution.
The search for a partner has been identified as a priority for the firm's recently appointed Head of Business Development and Licensing.
The partnership agreement with PT Pyridam Farma is set for an initial term expiring on 26 June 2030, with provisions for renewal.